EA201591137A1 - Ингибиторы mk2 и их применения - Google Patents
Ингибиторы mk2 и их примененияInfo
- Publication number
- EA201591137A1 EA201591137A1 EA201591137A EA201591137A EA201591137A1 EA 201591137 A1 EA201591137 A1 EA 201591137A1 EA 201591137 A EA201591137 A EA 201591137A EA 201591137 A EA201591137 A EA 201591137A EA 201591137 A1 EA201591137 A1 EA 201591137A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitors
- applications
- compositions
- methods
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Abstract
В настоящем изобретении предложены соединения, их композиции и способы их применения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361794310P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/011501 WO2014149164A1 (en) | 2013-03-15 | 2014-01-14 | Mk2 inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201591137A1 true EA201591137A1 (ru) | 2016-02-29 |
Family
ID=51580575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591137A EA201591137A1 (ru) | 2013-03-15 | 2014-01-14 | Ингибиторы mk2 и их применения |
Country Status (11)
Country | Link |
---|---|
US (2) | US10138256B2 (ru) |
EP (1) | EP2968339A4 (ru) |
JP (1) | JP2016518316A (ru) |
KR (2) | KR20150133172A (ru) |
CN (2) | CN110746424A (ru) |
AU (3) | AU2014238443A1 (ru) |
CA (1) | CA2908098A1 (ru) |
EA (1) | EA201591137A1 (ru) |
HK (1) | HK1220355A1 (ru) |
MX (1) | MX2015008999A (ru) |
WO (1) | WO2014149164A1 (ru) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
CN102382106A (zh) * | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
KR20150133172A (ko) | 2013-03-15 | 2015-11-27 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Mk2 억제제 및 이의 용도 |
DK3057943T3 (en) | 2013-10-18 | 2018-07-30 | Eisai R&D Man Co Ltd | PYRIMIDINE-FGFR4 INHIBITORS |
US10512651B2 (en) * | 2014-08-25 | 2019-12-24 | Stc.Unm | Inhibition of MK2 in the treatment of cancer |
ES2874561T3 (es) * | 2014-09-17 | 2021-11-05 | Celgene Car Llc | Inhibidores de MK2 y usos de los mismos |
CN105693727B (zh) * | 2014-11-27 | 2018-10-16 | 上海合全药业股份有限公司 | 8-(叔丁氧羰基)-6,7,8,9-四氢-5-氢-咪唑[1,5-a][1,4]二氮杂-6-羧酸的合成方法 |
JP6480728B2 (ja) * | 2014-12-26 | 2019-03-13 | 住友化学株式会社 | 化合物 |
ES2899196T3 (es) * | 2015-03-09 | 2022-03-10 | Aurigene Discovery Tech Ltd | Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK |
JP6861166B2 (ja) | 2015-03-27 | 2021-04-21 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
WO2016164703A1 (en) * | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
ES2864712T3 (es) | 2015-04-14 | 2021-10-14 | Eisai R&D Man Co Ltd | Compuesto inhibidor de FGFR4 cristalino y usos del mismo |
AU2015396809B2 (en) | 2015-06-03 | 2019-07-11 | Js Innopharm (Shanghai) Ltd. | Heterocyclic compounds for treating psoriasis |
WO2016192063A1 (en) * | 2015-06-03 | 2016-12-08 | Changzhou Jiekai Pharmatech Co. Ltd | Heterocyclic compounds as erk inhibitors |
PL3319959T3 (pl) | 2015-07-06 | 2022-02-14 | Alkermes, Inc. | Hetero-haloinhibitory deacetylazy histonowej |
US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
CA2996978A1 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CA3228632A1 (en) * | 2015-12-24 | 2017-06-29 | Kyowa Kirin Co., Ltd. | .alpha.,.beta.-unsaturated amide compound |
US10059718B2 (en) | 2016-01-04 | 2018-08-28 | Tabomedex Biosciences, LLC | Fused quadracyclic compounds, compositions and uses thereof |
US11357769B2 (en) | 2016-05-10 | 2022-06-14 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
US10703741B2 (en) * | 2016-07-27 | 2020-07-07 | Padlock Therapeutics, Inc. | Covalent inhibitors of PAD4 |
CN106810460A (zh) * | 2016-12-30 | 2017-06-09 | 苏州诚和医药化学有限公司 | 一种4‑[2‑(二甲基氨基)乙氧基]苄胺的制备方法 |
JP6756925B2 (ja) | 2017-01-11 | 2020-09-16 | ロダン・セラピューティクス,インコーポレーテッド | ヒストンデアセチラーゼの二環式阻害剤 |
EP3595658A4 (en) | 2017-03-16 | 2020-11-25 | Celgene CAR LLC | FORMS AND COMPOSITIONS OF A MK2 INHIBITOR |
AU2018236290B2 (en) * | 2017-03-16 | 2022-06-02 | Bristol-Myers Squibb Company | MK2 inhibitors, synthesis thereof, and intermediates thereto |
JP2020511468A (ja) | 2017-03-16 | 2020-04-16 | セルジーン シーエーアール エルエルシー | Mk2阻害剤の重水素化アナログおよびその使用 |
EP3596084A4 (en) * | 2017-03-16 | 2020-12-23 | Celgene CAR LLC | 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4.5] THIENO [3,2-F] QUINOLINE-8-ON COMPOUNDS AND USES THEREOF |
WO2018170200A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
JP7152471B2 (ja) | 2017-08-07 | 2022-10-12 | ロダン・セラピューティクス,インコーポレーテッド | ヒストン脱アセチル化酵素の二環阻害剤 |
CN107382853A (zh) * | 2017-09-05 | 2017-11-24 | 中国药科大学 | 3-芳基喹啉类化合物、其制备方法和医药用途 |
JP6923170B2 (ja) * | 2017-12-27 | 2021-08-18 | 株式会社ルネッサンス・エナジー・リサーチ | Co2除去方法及び装置 |
CN108658860B (zh) * | 2018-07-17 | 2020-11-27 | 成都睿智化学研究有限公司 | 一种3-氯-5,6,7,8-四氢异喹啉的制备方法 |
KR102615234B1 (ko) | 2018-09-21 | 2023-12-19 | 화이자 인코포레이티드 | Ccr6 억제제로서 유용한 n-치환된-디옥소시클로부테닐아미노-3-히드록시-피콜린아미드 |
TW202322824A (zh) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
US20230322767A1 (en) | 2020-07-29 | 2023-10-12 | Bayer Aktiengesellschaft | Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof |
MX2023003264A (es) | 2020-09-21 | 2023-06-06 | Prelude Therapeutics Inc | Inhibidores de cdk y su uso como productos fármaceuticos. |
CN116323571A (zh) * | 2020-10-23 | 2023-06-23 | 丹娜法伯癌症研究院 | 肌酸激酶(ck)的共价抑制剂以及其用于治疗和预防癌症的用途 |
CN117120444A (zh) | 2021-04-16 | 2023-11-24 | 吉利德科学公司 | 使用酰胺制备卡巴核苷的方法 |
WO2023278759A1 (en) * | 2021-06-30 | 2023-01-05 | Kymera Therapeutics, Inc. | Mk2 degraders and uses thereof |
CN113402523B (zh) * | 2021-07-13 | 2022-07-12 | 西安交通大学 | 一种靶向肥大细胞MrgX2小分子荧光探针及制备方法和应用 |
WO2023025298A1 (zh) * | 2021-08-27 | 2023-03-02 | 瑞石生物医药有限公司 | 喹啉并呋喃衍生物及其用途 |
CN116444492A (zh) * | 2021-12-29 | 2023-07-18 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
WO2023236960A1 (zh) * | 2022-06-07 | 2023-12-14 | 上海科恩泰生物医药科技有限公司 | 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途 |
CN115925718A (zh) * | 2022-12-27 | 2023-04-07 | 瑞石生物医药有限公司 | 一种四环内酰胺衍生物及其用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7167802B2 (en) * | 2002-11-13 | 2007-01-23 | Wyeth | Methods for identifying agents that interact with MAP kinase activated protein kinase 2 |
EP1572693A1 (en) | 2002-12-20 | 2005-09-14 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
PE20080668A1 (es) | 2006-08-30 | 2008-07-17 | Novartis Ag | Compuestos heterociclicos como inhibidores de la cinasa-2 de proteina activada por cinasa de proteina activada por mitogeno |
KR101315610B1 (ko) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
JP2010533674A (ja) | 2007-07-16 | 2010-10-28 | ノバルティス アーゲー | Mk2阻害剤として有用なヘテロ環式化合物 |
KR20110025224A (ko) | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
WO2010028236A1 (en) * | 2008-09-05 | 2010-03-11 | Avila Therapeutics, Inc. | Algorithm for designing irreversible inhibitors |
CA2780290C (en) * | 2009-12-14 | 2018-01-02 | Msd Oss B.V. | Mk2 inhibitors |
PL2544536T3 (pl) * | 2010-03-11 | 2019-05-31 | Kempharm Inc | Koniugaty kwasów tłuszczowych z kwetiapiną, sposób ich wytwarzania i stosowania |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
US9085586B2 (en) | 2012-07-11 | 2015-07-21 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
KR20150133172A (ko) | 2013-03-15 | 2015-11-27 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Mk2 억제제 및 이의 용도 |
ES2874561T3 (es) | 2014-09-17 | 2021-11-05 | Celgene Car Llc | Inhibidores de MK2 y usos de los mismos |
-
2014
- 2014-01-14 KR KR1020157018816A patent/KR20150133172A/ko active Application Filing
- 2014-01-14 AU AU2014238443A patent/AU2014238443A1/en not_active Abandoned
- 2014-01-14 CA CA2908098A patent/CA2908098A1/en not_active Abandoned
- 2014-01-14 CN CN201910894630.0A patent/CN110746424A/zh active Pending
- 2014-01-14 MX MX2015008999A patent/MX2015008999A/es unknown
- 2014-01-14 KR KR1020217021981A patent/KR20210091832A/ko active Application Filing
- 2014-01-14 WO PCT/US2014/011501 patent/WO2014149164A1/en active Application Filing
- 2014-01-14 US US14/760,697 patent/US10138256B2/en active Active
- 2014-01-14 JP JP2016500164A patent/JP2016518316A/ja active Pending
- 2014-01-14 EA EA201591137A patent/EA201591137A1/ru unknown
- 2014-01-14 CN CN201480004727.5A patent/CN105163738A/zh active Pending
- 2014-01-14 EP EP14769652.0A patent/EP2968339A4/en not_active Withdrawn
-
2016
- 2016-07-15 HK HK16108382.1A patent/HK1220355A1/zh unknown
-
2018
- 2018-11-19 US US16/194,577 patent/US11098061B2/en active Active
-
2019
- 2019-07-11 AU AU2019204981A patent/AU2019204981A1/en not_active Abandoned
-
2021
- 2021-02-11 AU AU2021200884A patent/AU2021200884A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1220355A1 (zh) | 2017-05-05 |
CA2908098A1 (en) | 2014-09-25 |
JP2016518316A (ja) | 2016-06-23 |
EP2968339A1 (en) | 2016-01-20 |
MX2015008999A (es) | 2015-09-16 |
US20190135835A1 (en) | 2019-05-09 |
KR20210091832A (ko) | 2021-07-22 |
KR20150133172A (ko) | 2015-11-27 |
US11098061B2 (en) | 2021-08-24 |
CN105163738A (zh) | 2015-12-16 |
US10138256B2 (en) | 2018-11-27 |
CN110746424A (zh) | 2020-02-04 |
US20150376208A1 (en) | 2015-12-31 |
AU2014238443A1 (en) | 2015-07-30 |
AU2019204981A1 (en) | 2019-08-01 |
EP2968339A4 (en) | 2017-02-15 |
WO2014149164A1 (en) | 2014-09-25 |
AU2021200884A1 (en) | 2021-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591137A1 (ru) | Ингибиторы mk2 и их применения | |
CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
EA201591961A1 (ru) | Ингибиторы акк и их применение | |
TR201811764T4 (tr) | Kinaz inhibitörleri olarak aminoheteroaril benzamidleri. | |
EA201591959A1 (ru) | Ингибиторы акк и их применение | |
EA201890749A1 (ru) | ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ | |
EA201591960A1 (ru) | Ингибиторы акк и их применение | |
MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
EA201690613A1 (ru) | Улучшенные составы на основе аденовирусов | |
CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
EA201591420A1 (ru) | Гетероарильные соединения и их применение | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
EA201591962A1 (ru) | Ингибиторы акк и их применение | |
UY34763A (es) | Inhibidores de la agregación plaquetaria | |
DK2986726T3 (da) | Hidtil ukendte bacillusstammesammensætninger | |
EA201690764A1 (ru) | Ингибитор грелин-o-ацилтрансферазы | |
EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
UY4223Q (es) | Banco | |
MX2014015039A (es) | Inhibidores de fbx03. | |
ES2651188T8 (es) | Composición líquida fotopolimerizable | |
EA201591709A1 (ru) | 5-бром-индирубины | |
EA202092926A3 (ru) | Лиофилизированные составы, содержащие фактор ix | |
UY4314Q (es) | Configuracion aplicada en zapato | |
DK3237407T3 (da) | 3,5-diaminopyrazolkinasehæmmere |